Overview

A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy

Status:
Terminated

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

This is a single-arm, open label, two stage, phase II study of dovitinib in patients with advanced Malignant Pleural Mesothelioma (MPM). The primary purpose of this study is to evaluate the potential efficacy of dovitinib in the second- or third-line treatment of MPM using progression free survival (PFS).

Phase:

Phase 2

Details

Lead Sponsor:

Ontario Clinical Oncology Group (OCOG)

Collaborator:

Novartis Pharmaceuticals

Treatments:

Folic Acid Antagonists